Lexicon Pharmaceuticals | LXRX - Debt


Lexicon Pharmaceuticals reported $99.51M in Debt for its fiscal quarter ending in December of 2023.





Debt Change Date
Abbott USD 34.05B 20.19B Mar/2026
Acadia Pharmaceuticals USD 50.79M 1.39M Mar/2026
Agios Pharmaceuticals USD 35.74M 4.46M Mar/2026
Akebia Therapeutics USD 46.51M 7.82M Mar/2025
Alnylam Pharmaceuticals USD 1.27B 5.33M Mar/2026
AstraZeneca USD 32.24B 1.68B Jun/2026
BioMarin Pharmaceutical USD 1.44B 833.74M Mar/2026
Coherus Biosciences USD 294.92M 1.25M Mar/2025
Eli Lilly USD 43.37B 867M Mar/2026
Halozyme Therapeutics USD 2.14B 2.01M Mar/2026
Illumina USD 2.54B 9M Mar/2026
Insmed USD 725.8M 1.82M Jun/2026
Ironwood Pharmaceuticals USD 583.99M 14.83M Dec/2024
J&J USD 54.99B 7.05B Mar/2026
Lexicon Pharmaceuticals USD 99.51M 243K Dec/2023
MacroGenics USD 36.51M 500K Mar/2026
MannKind USD 330.96M 36.48M Mar/2026
Merck USD 49.12B 222M Mar/2026
Moderna USD 1.3B 7M Mar/2026
Novartis USD 49.01B 2.02B Jun/2026
PTC Therapeutics USD 286.94M 2.42B Mar/2026
Puma Biotechnology USD 89.06M 55.07M Jun/2024
Sarepta Therapeutics USD 1.04B 3.08M Mar/2026
Thermo Fisher Scientific USD 43.16B 3.78B Mar/2026
Ultragenyx Pharmaceutical USD 36M 2.17M Dec/2025
United Therapeutics USD 200M 100M Mar/2025
Vanda Pharmaceuticals USD 4.96M 4.96M Dec/2024